Demographics and baseline characteristics
| Characteristic | Abatacept plus MTX (n=119) | Abatacept monotherapy (n=116) | MTX (n=116) | Total (N=351) |
|---|---|---|---|---|
| Age—year (median) | 46.4±13.2 (45.0) | 45.4±11.9 (45.0) | 49.1±12.4 (49.0) | 47.0±12.6 (47.0) |
| Weight—kg (median) | 73.0±17.7 (68.7) | 72.1±16.8 (69.5) | 74.1±17.1 (71.5) | 73.1±17.2 (69.9) |
| Female sex—number (%) | 95 (79.8) | 89 (76.7) | 89 (76.7) | 273 (77.8) |
| White race—number (%) | 100 (84.0) | 95 (81.9) | 102 (87.9) | 297 (84.6) |
| Geographic region—number (%) | ||||
| North America | 17 (14.3) | 21 (18.1) | 15 (12.9) | 53 (15.1) |
| South America | 26 (21.8) | 24 (20.7) | 25 (21.6) | 75 (21.4) |
| Europe | 47 (39.5) | 42 (36.2) | 48 (41.4) | 137 (39.0) |
| ROW | 29 (24.4) | 29 (25.0) | 28 (24.1) | 86 (24.5) |
| RA symptom duration—year | 0.58±0.50 | 0.59±0.52 | 0.50±0.49 | 0.56±0.50 |
| RA symptom duration <3 months—number (%) | 36 (30.3) | 36 (31.0) | 48 (41.4) | 120 (34.2) |
| RF positive—number (%) | 113 (95.0) | 111 (95.7) | 110 (94.8) | 334 (95.2) |
| Tender joint count (28 joints) | 14.0±7.7 | 14.0±7.6 | 12.8±7.8 | 13.6±7.7 |
| Swollen joint count (28 joints) | 11.2±6.9 | 11.4±7.66 | 10.7±7.0 | 11.1±7.1 |
| CRP—mg/L | 18.1±28.4 | 16.9±23.9 | 17.3±22.4 | 17.5±25.0 |
| Patient global assessment (0–100 mm VAS) | 62.7±21.0 | 57.3±22.4 | 58.2±19.7 | 59.4±21.1 |
| Physician global assessment (0–100 mm VAS) | 58.4±19.1 | 58.7±20.6 | 58.6±20.3 | 58.6±20.0 |
| DAS28 (CRP) | 5.5±1.3 | 5.5±1.1 | 5.3±1.3 | 5.4±1.2 |
| HAQ-DI | 1.5±0.68 | 1.4±0.66 | 1.4±0.65 | 1.4±0.66 |
| Pain (0–100 mm VAS) | 62.4±20.8 | 61.3±21.6 | 59.5±18.3 | 61.1±20.3 |
| Physical function (0–100, Short Form-36 subscale) | 38.5±25.9 | 41.6±25.6 | 39.1±24.5 | 39.7±25.3 |
Plus-minus values are means±SD.
CRP, C reactive protein; DAS, Disease Activity Score; HAQ-DI, Health Assessment Questionnaire-Disability Index; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; ROW, rest of the world; VAS, visual analogue scale.